C12N 2710/10311
Mastadenovirus
Official title: Mastadenovirus, e.g. human or simian adenoviruses
C12N2710/10311 (Mastadenovirus) appears on 1,809 US grants and 2,992 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,809
- Published applications
- 2,992
- Assignees
- 1,020
- Inventors
- 4,257
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 2 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 3 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 12 | 0 |
| 1997 | 20 | 0 |
| 1998 | 43 | 0 |
| 1999 | 56 | 0 |
| 2000 | 62 | 0 |
| 2001 | 68 | 29 |
| 2002 | 75 | 165 |
| 2003 | 76 | 198 |
| 2004 | 62 | 151 |
| 2005 | 48 | 147 |
| 2006 | 72 | 131 |
| 2007 | 65 | 124 |
| 2008 | 45 | 102 |
| 2009 | 55 | 108 |
| 2010 | 52 | 110 |
| 2011 | 45 | 101 |
| 2012 | 55 | 81 |
| 2013 | 42 | 62 |
| 2014 | 48 | 75 |
| 2015 | 55 | 79 |
| 2016 | 53 | 84 |
| 2017 | 56 | 92 |
| 2018 | 61 | 108 |
| 2019 | 72 | 130 |
| 2020 | 76 | 135 |
| 2021 | 72 | 145 |
| 2022 | 84 | 172 |
| 2023 | 80 | 149 |
| 2024 | 66 | 135 |
| 2025 | 79 | 117 |
| 2026 | 42 | 62 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/10341Use of virus, viral particle or viral elements as a vectorIndexing code1,552
- C12N 2710/10322New viral proteins or individual genes, new structural or functional aspects ofIndexing code428
- C12N 2710/10351Methods of production or purification of viral materialIndexing code268
- C12N 2710/10332Use of virus as therapeutic agent, other than vaccineIndexing code239
- C12N 2710/10321Viruses as suchIndexing code163
- C12N 2710/10334Use of virus or viral component as vaccineIndexing code89
- C12N 2710/10371Demonstrated in vivo effectIndexing code76
- C12N 2710/10361Methods of inactivation or attenuationIndexing code72
Recent patents
- Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis6 Oct 2026US 12,753,384 B2Cornell Research Foundation, Inc.
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis in humans, and compositions comprising the same25 Aug 2026US 12,714,755 B2Pacira Therapeutics, Inc.
- Rescue of recombinant adenoviruses by CRISPR/Cas-mediated in vivo terminal resolution25 Aug 2026US 12,716,064 B2Albert-Ludwigs-Universität Freiburg
- Adenovirus vector circular rna expression system8 Oct 2026US 2026/0306666 A1
- Hiv immunogenic polypeptides and vaccines and uses thereof24 Sep 2026US 2026/0284175 A1Gilead Sciences, Inc.
- A viral vector and a vaccine composition comprising the vector24 Sep 2026US 2026/0284181 A1Rokote Laboratories Finland Oy
- Methods and compositions for cancer treatment using recombinant polypeptides24 Sep 2026US 2026/0284226 A1Infinitopes Limited
- Compositions and methods for recombinant aav production24 Sep 2026US 2026/0286386 A1REGENXBIO Inc.
Most cited
By later US patents
- Hybrid adenovirus-AAV virus and methods of use thereof311US 5,871,982 AThe Trustees of the University of Pennsylvania · 1999
- Vectors and methods for immunization or therapeutic protocols285US 6,339,068 B12002
- Adenovirus vectors for gene therapy278US 5,585,362 AThe Regents of the University of Michigan · 1996
- Packaging systems for human recombinant adenovirus to be used in gene therapy267US 5,994,128 AIntrogene B.V. · 1999
- Composition for introducing nucleic acid complexes into higher eucaryotic cells257US 5,547,932 ABoehringer Ingelheim International GmbH · 1996